TELA Bio/TELA

$4.75

-7.76%
-
1D1W1MYTD1YMAX

About TELA Bio

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

Ticker

TELA

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Antony Koblish

Employees

227

Headquarters

Malvern, United States

TELA Bio Metrics

BasicAdvanced
$127.44M
Market cap
-
P/E ratio
-$2.06
EPS
0.96
Beta
-
Dividend rate
$127.44M
0.95849
$11.26
$4.23
127.79K
4.227
3.452
214.581
214.581
-8.44%
-63.97%
-281.23%
-80.09%
2.18
6.707
7.603
41.13%
25.77%
47.51%

What the Analysts think about TELA Bio

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
207.37% upside
High $18.00
Low $12.00
$4.75
Current price
$14.60
Average price target

TELA Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-75.73% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$16.9M
12.67%
Net income
$-12.8M
17.43%
Profit margin
-75.73%
4.23%

TELA Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 21.9%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.63
-$0.46
-$0.45
-$0.53
-
Expected
-$0.56
-$0.53
-$0.49
-$0.43
-$0.50
Surprise
12.66%
-13.7%
-8.5%
21.9%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for TELA Bio stock?

TELA Bio (TELA) has a market cap of $127.44M as of April 19, 2024.

What is the P/E ratio for TELA Bio stock?

The price to earnings (P/E) ratio for TELA Bio (TELA) stock is 0 as of April 19, 2024.

Does TELA Bio stock pay dividends?

No, TELA Bio (TELA) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next TELA Bio dividend payment date?

TELA Bio (TELA) stock does not pay dividends to its shareholders.

What is the beta indicator for TELA Bio?

TELA Bio (TELA) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the TELA Bio stock price target?

The target price for TELA Bio (TELA) stock is $14.6, which is 207.37% above the current price of $4.75. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell TELA Bio stock

Buy or sell TELA Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing